Baylor University Medical Center, Baylor Scott & White Health, Dallas, Texas.
Baylor University Medical Center, Baylor Scott & White Health, Dallas, Texas.
Clin Gastroenterol Hepatol. 2022 Aug;20(8S):S9-S19. doi: 10.1016/j.cgh.2022.04.034.
Hepatic encephalopathy (HE) is a potentially reversible neurocognitive complication of cirrhosis. It has been reported in at least 30% of patients with cirrhosis and imposes a significant economic burden on caregivers and the healthcare system. Ammonia has been recognized as the culprit in HE development, and all the currently approved treatments mostly act on this toxin to help with HE resolution. After a brief overview of HE characteristics and pathophysiology, this review explores the current accepted treatments for this debilitating complication of cirrhosis. This is followed by an overview of the novel available therapies and a brief focus on future treatment modalities for HE.
肝性脑病（HE）是肝硬化潜在的可逆转的神经认知并发症。据报道，至少 30%的肝硬化患者存在这种并发症，这给护理人员和医疗保健系统带来了巨大的经济负担。氨已被认为是 HE 发展的罪魁祸首，目前所有批准的治疗方法主要作用于这种毒素，以帮助解决 HE。本文简要概述了 HE 的特征和病理生理学，探讨了目前对肝硬化这一严重并发症的治疗方法。随后概述了新的可用疗法，并简要关注了 HE 的未来治疗方式。
